Spending power
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Key facts
Counted staff
6
self-reported band not used
Founded
Not recorded
Registry matches
1
ABR
Office countries
1
1 address
Funding rounds
None on record
Company type
Public Company
self-reported
Legal entity
1 brand → 1 possible registrationThese are name matches on ABR. 1 registration share this brand's name; which one you contract with is a question for the register.
MYOPHARM LIMITED
ABN20133150884
Legal entities
Show as table · Myopharm Limited: 1 registry entity
| MYOPHARM LIMITED | ABN 20133150884 |
|---|---|
| Confirmed matches | 0 of 1 |
A candidate is a name match on the registry, not a confirmed identity, and two candidates are ambiguity rather than a corporate structure.
Description
Myopharm Limited is a clinical-stage Australian-based biopharmaceutical company, developing targeted therapies for multiple chronic diseases.
In our portfolio we have pharmaceutical drug candidates & clinically validated consumer health products.
Our lead drug asset TriGlytza is at IND stage and as a biotechnology company we are focused on developing first-in-class, novel therapeutics and consumer products for the treatment and prevention of Type 2 diabetes.
Myopharm is currently developing a number of diabetes therapeutics including a beta-cell-centric triple combination drug, to address the 50% antidiabetic treatment failures occurring in Type 2 diabetics.
Right now, there are no anti-inflammatory 'Beta-cell-centric' therapies on the market for Type 2 diabetes. Our novel & innovative beta-cell centric product, RK-01 or TriGlytza™ restored the efficacy of Metformin in C57BL/6J DIO mice with insulin resistance and pancreatic beta-cell dysfunction. We are on track to bring TriGlytza™ to market by 2027.
https://www.myopharm.com
Specialties
All 15 specialties
- Biotechnology
- Therapeutics
- Orphan / Rare Diseases
- metabolic diseases
- diabetes
- metabolic syndromes
- T2D
- R&D
- type 2 Diabetes
- Pre-Diabetes
- Insulin Resistance
- IND Approved
- Beta-cell-centric
- weightloss
- endocrinology
Locations
Country footprint
Show as table · Offices in 1 country
| Countries | 1 |
|---|---|
| Primary country | AU |
All codes: AU
Addresses
- AU60 Martin Pl; Levels 1,2&3; Sydney, New South Wales 2000Primary
Grid intelligence Members
Signals & hiring
Hiring, headcount and registry-change signals, streamed to members.
Latest signal
Hiring activity
Headcount trend
Financials
Registry-filed capital and financial indicators, standardised by TheGrid.
Paid-up capital
Fiscal period
Registered charges
Revenue
Profit / loss
People & contacts
3 employee profiles on record · names withheld.
Names and titles are intentionally absent from this page. The source relation carries no consent record across the privacy regimes this directory spans, so it is never requested and never stored. Search engines see exactly what you see here.
Counts only. No names are stored here, and none are served.
FAQ
Which legal entity operates under Myopharm Limited?
One New South Wales entity on the ABR. MYOPHARM LIMITED (ABN 20 133 150 884), medium confidence.
How many people work at Myopharm Limited?
The record holds 6 counted staff profiles at January 2026. Its self-reported band sits above that count and is not published as a headcount.
Where does Myopharm Limited have offices?
One address on record, Australia only. Primary: 60 Martin Pl, Levels 1, 2&3, Sydney, New South Wales 2000.
Has Myopharm Limited raised funding?
None linked to this brand.
What does Myopharm Limited list as its specialties?
15 tags on the brand's own list, among them r&d, diabetes and endocrinology.
Which companies are listed alongside Myopharm Limited?
5 profiles list Myopharm Limited as a peer — 60th percentile in Biotechnology. It lists ten peers of its own. Actinogen Medical and Radiancy Group Pty Ltd list it back.